  | Chung, K., Jiang, D., Gu, X., Xu, J., GREGOIRE, C., Coutinho De Oliveira, B., Jha, B. K., & Melenhorst, J. J. (05 November 2024). Metabolic Reprogramming By IDH1 Neomorph Epigenetically Guides CAR T Cell Differentiation. Blood, 144 (Supplement 1), 1035-1035. doi:10.1182/blood-2024-205836  Peer Reviewed verified by ORBi |
  | Bai, Z.* , Feng, B.* , McClory, S. E., de Oliveira, B. C., Diorio, C., GREGOIRE, C., Tao, B., Yang, L., Zhao, Z., Peng, L., Sferruzza, G., Zhou, L., Zhou, X., Kerr, J., Baysoy, A., Su, G., Yang, M., Camara, P. G., Chen, S., ... Fan, R. (2024). Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission. Nature. doi:10.1038/s41586-024-07762-w Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Arunachalam, A. K., GREGOIRE, C., Coutinho de Oliveira, B., & Melenhorst, J. J. (2024). Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies. Blood Reviews, 101241. doi:10.1016/j.blre.2024.101241 Peer Reviewed verified by ORBi |
 | GREGOIRE, C., Coutinho de Oliveira, B., Caimi, P. F., Caers, J., & Melenhorst, J. J. (2024). Chimeric antigen receptor T-cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice. British Journal of Haematology. doi:10.1111/bjh.19751 Peer Reviewed verified by ORBi |
 | Zhao, Z., Grégoire, C., Oliveira, B., Chung, K., & Melenhorst, J. J. (January 2023). Challenges and opportunities of CAR T-cell therapies for CLL. Seminars in Hematology, 60 (1), 25 - 33. doi:10.1053/j.seminhematol.2023.01.002 Peer Reviewed verified by ORBi |
 | El Moussaoui, M., Desmecht, S., Lambert, N., Maes, N., Braghini, J., MARECHAL, N., Quintana, C., BRIQUET, K., Gofflot, S., Toussaint, F., Hayette, M.-P., Vermeersch, P., Lutteri, L., GREGOIRE, C., Beguin, Y., Rahmouni, S., Moutschen, M., Desmecht, D., & Darcis, G. (2023). Cluster Analysis Identifies Distinct Patterns of T-Cell and Humoral Immune Responses Evolution Following a Third Dose of SARS-CoV-2 Vaccine in People Living with HIV. Viruses, 15, 1435. doi:10.3390/v15071435 Peer Reviewed verified by ORBi Dataset: 10.3390/v15071435 |
 | El Moussaoui, M., Desmecht, S., Tashkeev, A., Lambert, N., Maes, N., Braghini, J., MARECHAL, N., Quintana, C., BRIQUET, K., Gofflot, S., TOUSSAINT, F., Hayette, M.-P., Vermeersch, P., Lutteri, L., Grégoire, C., Beguin, Y., Rahmouni, S., Moutschen, M., Desmecht, D., & Darcis, G. (05 September 2022). Reduced T-cell response following a third dose of SARS-CoV-2 vaccine in infection-naïve people living with HIV. Journal of Infection, 85, 751-755. doi:10.1016/j.jinf.2022.09.006 Peer Reviewed verified by ORBi |
 | GREGOIRE, C.* , LAYIOS, N.* , LAMBERMONT, B., LECHANTEUR, C., BRIQUET, A., Bettonville, V., BAUDOUX, E., THYS, M., Dardenne, N., Misset, B.* , & BEGUIN, Y.*. (04 July 2022). Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial. Frontiers in Immunology, 13, 932360. doi:10.3389/fimmu.2022.932360 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | El Moussaoui, M., Maes, N., Hong, S. L., Lambert, N., Gofflot, S., DELLOT, P., Belhadj, Y., Huynen, P., Hayette, M.-P., Meex, C., Bontems, S., Defêche, J., Godderis, L., Molenberghs, G., Meuris, C., Artesi, M., Durkin, K., Rahmouni, S., GREGOIRE, C., ... DARCIS, G. (14 June 2022). Evaluation of Screening Program and Phylogenetic Analysis of SARS-CoV-2 Infections among Hospital Healthcare Workers in Liège, Belgium. Viruses, 14 (6), 1302. doi:10.3390/v14061302 Peer Reviewed verified by ORBi Dataset: 10.3390/v14061302 |
 | GREGOIRE, C.* , HUYNEN, P.* , Gofflot, S., Seidel, L., Maes, N., VRANKEN, L., DELCOUR, S., MOUTSCHEN, M., HAYETTE, M.-P., KOLH, P., MELIN, P., & BEGUIN, Y. (13 June 2022). Predictive factors for the presence and long-term persistence of SARS-CoV-2 antibodies in healthcare and university workers. Scientific Reports, 12, 9790. doi:10.1038/s41598-022-13450-4 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Kegyes, D.* , Constantinescu, C.* , Vrancken, L., Rasche, L., Grégoire, C., Tigu, B., Gulei, D., Dima, D., Tanase, A., Einsele, H., Ciurea, S., Tomuleasa, C., & Caers, J. (07 June 2022). Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? Journal of Hematology and Oncology, 15 (1), 78. doi:10.1186/s13045-022-01296-2 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | GREGOIRE, C., SERVAIS, S., WILLEMS, E., BAUDOUX, E., LECHANTEUR, C., BRIQUET, A., Bettonville, V., DETRY, O., ERPICUM, P., JOURET, F., LOUIS, E., BARON, F., & BEGUIN, Y. (April 2022). Immunothérapie cellulaire au CHU de Liège : avancées, défis et perspectives. Revue Médicale de Liège, 77 (4), 206-211. Editorial Reviewed verified by ORBi |
 | HUYNEN, P.* , GREGOIRE, C.* , GOFFLOT, S., SEIDEL, L., MAES, N., VRANKEN, L., DELCOUR, S., MOUTSCHEN, M., HAYETTE, M.-P., KOLH, P., MELIN, P., & BEGUIN, Y. (25 March 2022). Long-term longitudinal evaluation of the prevalence of SARS-CoV-2 antibodies in healthcare and university workers. Scientific Reports, 12 (1), 5156. doi:10.1038/s41598-022-09215-8 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Massart, N., Maxime, V., Fillatre, P., Razazi, K., Ferré, A., Moine, P., Legay, F., Voiriot, G., Amara, M., Santi, F., Nseir, S., Marque-Juillet, S., Bounab, R., Barbarot, N., Bruneel, F., Luyt, C.-E., the COVID ICU Bacteremia Study Group on behalf of the COVID-ICU Investigators, KISOKA, G. (Other coll.), GREGOIRE, C. (Other coll.), & Lambermont, B. (Other coll.). (January 2022). Correction to: Characteristics and prognosis of bloodstream infection in patients with COVID-19 admitted in the ICU: an ancillary study of the COVID-ICU study (Annals of Intensive Care, (2021), 11, 1, (183), 10.1186/s13613-021-00971-w). Annals of Intensive Care, 12 (1). doi:10.1186/s13613-022-00979-w Peer Reviewed verified by ORBi Dataset: 10.1186/s13613-022-00979-w |
 | COVID-ICU group, for the REVA network, COVID-ICU investigators, KISOKA, G., GREGOIRE, C., & LAMBERMONT, B. (08 December 2021). Benefits and risks of noninvasive oxygenation strategy in COVID-19: a multicenter, prospective cohort study (COVID-ICU) in 137 hospitals. Critical Care, 25 (1), 421. doi:10.1186/s13054-021-03784-2 Peer Reviewed verified by ORBi |
 | LAMBERMONT, B., COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators, KISOKA, G., & Grégoire, C. (2021). Clinical characteristics and day-90 outcomes of 4244 ctritically ill adults with COVID-19: a prospective cohort study. Intensive Care Medicine. doi:10.1007/s00134-020-06294-x Peer Reviewed verified by ORBi |
 | Ritacco, C.* , Ehx, G.* , GREGOIRE, C., Daulne, C., WILLEMS, E., SERVAIS, S., BEGUIN, Y., & Baron, F. (2021). High proportion of terminally-differentiated regulatory T cells after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 56, 1828-1841. doi:10.1038/s41409-021-01221-0 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | GREGOIRE, C. (2020). Mesenchymal stromal cell-based immunomodulation in graft-versus-host disease and Crohn's disease [Doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/260628 |
 | Delens, L., Ehx, G., SOMJA, J., Vrancken, L., Belle, L., SEIDEL, L., Grégoire, C., Fransolet, G., Ritacco, C., Hannon, M., DUBOIS, S., Beguin, Y., Baron, F., & Servais, S. (2019). In Vitro Th17-Polarized Human CD4(+) T Cells Exacerbate Xenogeneic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 25, 204-215. doi:10.1016/j.bbmt.2018.10.007 Peer Reviewed verified by ORBi |
 | Grégoire, C., Ritacco, C., Hannon, M., SEIDEL, L., Delens, L., Belle, L., DUBOIS, S., Veriter, S., LECHANTEUR, C., BRIQUET, A., Servais, S., Ehx, G., Beguin, Y., & Baron, F. (2019). Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model. Frontiers in Immunology, 10, 619. doi:10.3389/fimmu.2019.00619 Peer Reviewed verified by ORBi |
 | ERPICUM, P., WEEKERS, L., DETRY, O., BONVOISIN, C., DELBOUILLE, M.-H., GREGOIRE, C., BAUDOUX, E., BRIQUET, A., LECHANTEUR, C., MAGGIPINTO, G., SOMJA, J., Pottel, H., Baron, F., Jouret, F., & BEGUIN, Y. (2019). Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study. Kidney International, 95, 693-707. doi:10.1016/j.kint.2018.08.046 Peer Reviewed verified by ORBi |
 | GREGOIRE, C., BRIQUET, A., PIRENNE, C., LECHANTEUR, C., LOUIS, E.* , & BEGUIN, Y.*. (November 2018). Allogeneic mesenchymal stromal cells for refractory luminal Crohn's disease: A phase I-II study. Digestive and Liver Disease, 50 (11), 1251-1255. doi:10.1016/j.dld.2018.08.015 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Vrancken, L., Muller, J., Lejeune, M., Grégoire, C., Delens, L., Jaspers, A., Servais, S., DE PRIJCK, B., Baron, F., Caers, J., & Beguin, Y. (2018). Nouveautes dans la prise en charge du myelome. Revue Médicale Suisse, 14 (615), 1438-1442. Peer Reviewed verified by ORBi |
Delens, L., SERVAIS, S., Ehx, G., Vrancken, L., Fransolet, G., GREGOIRE, C., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, F., & BARON, F. (24 May 2017). Th17 cells impact on xenogeneic graft-versus-host disease [Poster presentation]. 2017 Immunology day FNRS-Immunology Doctoral School, Gosselies, Belgium. |
 | GREGOIRE, C., Louis, E., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., GIET, O., Beguin, Y., & BARON, F. (2017). The role of mesenchymal stromal cells in the treatment of ulcerative colitis and Crohn’s disease. In The Biology and Therapeutic Application of Mesenchymal Cells (pp. 730-753). Hoboken, United States: John Wiley & Sons, Inc. Peer reviewed |
 | GREGOIRE, C., LECHANTEUR, C., BRIQUET, A., BAUDOUX, E., BARON, F., LOUIS, E., & BEGUIN, Y. (2017). Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 45, 205-221. doi:10.1111/apt.13864 Peer Reviewed verified by ORBi |
 | GREGOIRE, C., DETRY, O., Jouret, F., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., Beguin, Y., & GIET, O. (2017). The use of mesenchymal stromal cells in solid organ transplantation. In The Biology and Therapeutic Application of Mesenchymal Cells (pp. 825-835). Hoboken, United States: John Willey & Sons, Inc. Peer reviewed |
Delens, L., SERVAIS, S., Ehx, G., Vrancken, L., Fransolet, G., GREGOIRE, C., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & BARON, F. (18 November 2016). Impact des cellules Th17 sur la GVH xénogénique [Paper presentation]. 16ème édition du congrès de la SFGM-TC, Société Francophone de Greffe de Moelle et de Thérapie Cellulaire, Liège, Belgium. |
 | Grégoire, C., GUIOT, J., Vertenoeil, G., WILLEMS, E., HAFRAOUI, K., CORHAY, J.-L., LOUIS, R., & BEGUIN, Y. (February 2016). Yellow nail syndrome after allogeneic haematopoietic stem cell transplantation in two patients with multiple myeloma. Acta Clinica Belgica, 71, 428-430. doi:10.1080/17843286.2015.1122872 Peer Reviewed verified by ORBi |
 | Grégoire, C., Beguin, Y., Hannon, M., DUBOIS, S., BAUDOUX, E., BRIQUET, A., LECHANTEUR, C., Ehx, G., & Baron, F. (29 January 2016). Umbilical cord mesenchymal stromal cells are superior to bone marrow and adipose tissue-derived mesenchymal stromal cells for the treatment of xenogeneic graft-versus-host disease in mice [Poster presentation]. 31th General Meeting of the Belgian Hematological Society. |
 | SERVAIS, S., GREGOIRE, C., BARON, F., WILLEMS, E., BRIQUET, A., BAUDOUX, E., DELLOYE, O., GIET, O., LECHANTEUR, C., & BEGUIN, Y. (2016). Multipotent mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Belgian Journal of Hematology, 7, 229-235. Peer Reviewed verified by ORBi |
 | Rowart, P., ERPICUM, P., Detry, O., WEEKERS, L., Grégoire, C., LECHANTEUR, C., BRIQUET, A., Beguin, Y., Krzesinski, J.-M., & Jouret, F. (2015). Mesenchymal Stromal Cell Therapy in Ischemia/Reperfusion Injury. Journal of Immunology Research, 602597. doi:10.1155/2015/602597 Peer Reviewed verified by ORBi |
 | DETRY, O., JOURET, F., VANDERMEULEN, M., ERPICUM, P., Delens, L., GREGOIRE, C., BRIQUET, A., WEEKERS, L., BAUDOUX, E., LECHANTEUR, C., & BEGUIN, Y. (December 2014). Cellules stromales mésenchymateuses et transplantation d'organes. Revue Médicale de Liège, 69, 53-56. Peer reviewed |
 | GREGOIRE, C., Nellessen, E., Defraigne, J.-O., & RADERMECKER, M. (November 2014). La prothèse valvulaire idéale n’existe toujours pas. Quels facteurs entrent en compte pour orienter les choix d’une valve mécanique ou biologique ? Revue Médicale de Liège, 69 (11), 600-604. Peer reviewed |
  | BRIQUET, A., GREGOIRE, C., Comblain, F., Servais, L., Zeddou, M., LECHANTEUR, C., & Beguin, Y. (2014). [RETRACTED] Human bone marrow, umbilical cord or liver mesenchymal stromal cells fail to improve liver function in a model of CCl4-induced liver damage in NOD/SCID/IL-2Ry(null) mice. Cytotherapy, 16, 1511-1518. doi:10.1016/j.jcyt.2014.07.003 Peer Reviewed verified by ORBi |
 | VANDERMEULEN, M., GREGOIRE, C., BRIQUET, A., LECHANTEUR, C., BEGUIN, Y., & DETRY, O. (2014). Rationale for the potential use of mesenchymal stromal cells in liver transplantation. World Journal of Gastroenterology, 20 (44), 16418-32. doi:10.3748/wjg.v20.i44.16418 Peer Reviewed verified by ORBi |
BRIQUET, A., Grégoire, C., Beguin, Y., & Gothot, A. (April 2012). Inhibition of the Jagged-1/Notch pathway increases the hematopoiesis-supportive activity of mesenchymal stem cells [Paper presentation]. ESH-EHA Workshop Anti-Inflammatory & Immune Modulatory Properties of MSCs, Mandelieu, France. |
BRIQUET, A., Grégoire, C., Beguin, Y., & Gothot, A. (January 2011). Inhibition of the Jagged-1/Notch pathway increases the hematopoiesis-supportive activity of mesenchymal stem cells [Poster presentation]. 26th General Meeting of the Belgian Hematological Society, Liège, Belgium. |
